Sei Investments Co. Acquires 14,849 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Sei Investments Co. boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 14.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,318 shares of the biopharmaceutical company's stock after buying an additional 14,849 shares during the period. Sei Investments Co. owned 0.10% of Catalyst Pharmaceuticals worth $2,428,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. American Century Companies Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 18.3% in the 4th quarter. American Century Companies Inc. now owns 157,409 shares of the biopharmaceutical company's stock valued at $3,285,000 after buying an additional 24,395 shares during the period. Quantbot Technologies LP grew its stake in shares of Catalyst Pharmaceuticals by 47.8% in the 4th quarter. Quantbot Technologies LP now owns 11,237 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 3,636 shares during the last quarter. Lingohr Asset Management GmbH acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth approximately $202,000. Magnetar Financial LLC lifted its position in shares of Catalyst Pharmaceuticals by 54.7% during the 4th quarter. Magnetar Financial LLC now owns 19,341 shares of the biopharmaceutical company's stock valued at $404,000 after acquiring an additional 6,841 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in shares of Catalyst Pharmaceuticals by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 31,655 shares of the biopharmaceutical company's stock worth $661,000 after buying an additional 4,996 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CPRX shares. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Bank of America reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird raised their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Trading Up 6.3 %

CPRX stock traded up $1.34 during mid-day trading on Wednesday, hitting $22.74. The stock had a trading volume of 2,316,884 shares, compared to its average volume of 1,138,895. The firm has a fifty day simple moving average of $22.68 and a 200 day simple moving average of $21.98. The firm has a market capitalization of $2.76 billion, a P/E ratio of 19.27, a P/E/G ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.